STORIES

FDA Action Suggests a Future for Medical Mushrooms (MMS)

By David Jenison on October 28, 2018

In August 2017, the Food & Drug Administration (FDA) designated MDMA a "breakthrough therapy" for the treatment of post-traumatic stress disorder (PTSD). One year later, the FDA has done the same for psilocybin (the psychoactive ingredient in psychedelic mushrooms) as a therapy for treatment-resistant depression. In both cases, the FDA bestowed the designation on specific therapies, with London-based COMPASS Pathways earning breakthrough status for its psilocybin therapy. 

"This is great news for patients," said George Goldsmith, the company's Executive Chairman, in a press statement. "We are excited to be taking this work forward with our clinical trial on psilocybin therapy for treatment-resistant depression. The FDA will be working closely with us to expedite the development process and increase the chances of getting this treatment to people suffering with depression as quickly as possible."

A Breakthrough Therapy designation means that preliminary clinical evidence suggests a particular therapy produces substantial improvement compared to therapies currently available. Now with FDA support, COMPASS Pathways will run the "first large-scale psilocybin therapy clinical trial for treatment-resistant depression" in Europe and North America. 

An FDA-approved study conducted this past summer by Dr. Robin Carhart-Harris, Head of the Psychedelic Research Group at Imperial College London, helped pave the way for the designation. 

"In our 2015 study, we provided psilocybin to 19 patients in a clinical setting, coupled with psychological support, and found promising signals of efficacy and safety as treatment for treatment-resistant depression," he explained. "The Breakthrough Therapy designation is a strong endorsement for the potential of psilocybin therapy. We look forward to learning more as further clinical studies are carried out, by our team at Imperial College as well as in COMPASS's multi-centre trial."

Photo credit: afgooey74/Flickr.

FDA Approves Medical Mushrooms Trial

Nick Georgiou Channels Colors and Codices in New Exhibit

Hemp Seeds Were Just Sent into Space for the First Time

Best Events Around the World for May 2019

Election Upset: Denver Decriminalizes Magic Mushrooms!

Changa, the Psychedelic Challenge to Pharmaceutical Pain Medication

Bridging the Gap: How the Church and Cannabis Can Help Communities

The No. 1 Argument for Cannabis Legalization

EMAN8: The Story of a Broke Kid Whose Music Dreams Came True

Ginesse: Cait Fairbanks Turns her Emmy-Nominated Talents toward Music

National Restaurant Association: Cannabis the Hottest Food Trend for 2019

THC More Therapeutic Than Previously Thought

Pluto TV Premieres Dope State, Gabriel Sunday’s Ode to Cali Culture, on 4/20

Weedcraft Inc. Challenges Your Cannabis Game

We Tried 22Red in Four Different Ways